Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: Results of a phase I study

Investigational New Drugs

Volumn 16, Issue 2, 1998, Pages 141-146

  Lüftner, Diana ^a   Flath, Bernd ^a   Akrivakis, Costa ^a   Mergenthaler, Hans Günther ^a   Ohnmacht, Ute ^b   Arning, Michael ^b   Possinger, Kurt ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Epirubicin; Gemcitabine; Metastatic breast cancer; Phase I study

Indexed keywords

EPIRUBICIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING;

EID: 0031759721     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006121608414     Document Type: Article

References (8)

1. Jensen OM, Esteve J, Moller H, Renard H: Cancer in the European Community and its member states. Eur J Cancer 26: 1167-1256, 1990
2. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris A: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995
3. Blackstein M, Vogel CL, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer 33 (suppl 8): S149, abstr 664, 1997
4. Spielmann M, Kalla S, Llombart-Cussac A, et al.: Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Eur J Cancer 33 (suppl 8): S149, abstr 663, 1997
5. García-Conde J, Lluch A, Pérez-Manga G, Palomero O, Alba E, Rueda A, Moreno Noguiera JA, Calvo E, Tarazona Y, Lopez-Martin E: Gemcitabine + doxorubicin in advanced breast cancer: final results from an early phase II study. Proc ASCO 16: 147a, 1997
6. Coukell AJ, Faulds D: Epirubicin: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the managment of breast cancer. Drugs 53: 453-482, 1997
7. Blomquist C, Elmoaa I, Rissanen P et al.: FEC (5-fluorouracil, epirubicin, cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial. Acta Oncol 31(2): 231-236, 1992
8. Ricotti L, Zoli W, Barzanti F, Dal Susino M, Frassineti GL, Casadei Diunchi D, Milandri C, Amadori D: Schedule dependent interaction among doxorubicin, paclitaxel and gemcitabine in human breast cancer cell line. Proc ASCO 17: 959, 1998